Evidence map›Paper›PMID 38192619›Full record

ArticleVaccine: X2024

Evaluation of luciferase and prefusion-stabilized F protein from respiratory syncytial virus mRNA/LNPs in pre-clinical models using jet delivery compared to needle and syringe.

Brian K Meyer, Debbie Nahas, Myunggi An, Andrew Danziger, Jeffrey Smith, Manish Patel, Shu-An Lin, Alexa Gleason, Kara Cox, Robert Capen and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine: X, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Brian K MeyerMerck & Co., Inc., West Point, PA, USA.
Debbie NahasMerck & Co., Inc., West Point, PA, USA.
Myunggi AnMerck & Co., Inc., West Point, PA, USA.
Andrew DanzigerMerck & Co., Inc., West Point, PA, USA.
Jeffrey SmithMerck & Co., Inc., West Point, PA, USA.
Manish PatelMerck & Co., Inc., West Point, PA, USA.
Shu-An LinMerck & Co., Inc., West Point, PA, USA.
Alexa GleasonMerck & Co., Inc., West Point, PA, USA.
Kara CoxMerck & Co., Inc., West Point, PA, USA.
Robert CapenMerck & Co., Inc., West Point, PA, USA.
John HoweMerck & Co., Inc., West Point, PA, USA.
Andrew BettMerck & Co., Inc., West Point, PA, USA.
United States Military Academy · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Described here is the evaluation of a luciferase (luc) and respiratory syncytial virus (RSV) messenger RNA / lipid nanoparticle (mRNA/LNP) vaccine using a Needle-free Injection System, Tropis®, from PharmaJet® (Golden, Colorado USA). Needle-free jet delivery offers an alternative to needle/syringe. To perform this assessment, compatibility studies with Tropis were first performed with a luc mRNA/LNP and compared to needle/syringe. Although minor changes in particle size and encapsulation efficiency were observed when using Tropis on the benchtop,

Indexed as

Jet deliverymRNA/LNPRSVVaccine

Identifiers

PMID38192619
PMCPMC10772402
OpenAlexW4389510072

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.